(‐)‐Deprenyl alleviates the degenerative changes induced in the neonatal rat spinal cord by CSF from amyotrophic lateral sclerosis patients

References

• Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688–1700.
   PubMed Web of Science ®Google Scholar
• Strong M, Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 136–143.
   PubMed Web of Science ®Google Scholar
• Strong MJ. The basic aspects of therapeutics in amyotrophic lateral sclerosis. Pharmacol Ther 2003; 98: 379–414.
   PubMed Web of Science ®Google Scholar
• Festoff BW, Suo Z, Citron BA. Prospects for the pharmacotherapy of amyotrophic lateral sclerosis: old strategies and new paradigms for the third millennium. CNS Drugs 2003; 17: 699–717.
   PubMedGoogle Scholar
• Louvel E, Hugon J, Doble A. Therapeutic advances in amyo- trophic lateral sclerosis. Trends Pharmacol Sci 1997; 18: 196–203.
   PubMed Web of Science ®Google Scholar
• Krieger C, Hu JH, Pelech S. Aberrant protein kinases and phosphoproteins in amyotrophic lateral sclerosis. Trends Phar- macol Sci 2003; 24: 535–541.
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyo- trophic lateral sclerosis. Nature 1993; 362: 59–62.
   Google Scholar
• Shahani N, Gourie-Devi M, Nalini A, Raju TR. Cyclopho- sphamide attenuates the degenerative changes induced by CSF from patients with amyotrophic lateral sclerosis in the neonatal rat spinal cord. J Neurol Sci 2001; 185: 109–118.
   PubMed Web of Science ®Google Scholar
• Shahani N, Nalini A, Gourie-Devi M, Raju TR. Reactive astrogliosis in neonatal rat spinal cord after exposure to cerebrospinal fluid from patients with amyotrophic lateral sclerosis. Exp Neurol 1998; 149: 295–298.
   PubMed Web of Science ®Google Scholar
• Rao MS, Devi MG, Nalini A, Shahani N, Raju TR. Neurofilament phosphorylation is increased in ventral horn neurons of neonatal rat spinal cord exposed to cerebrospinal fluid from patients with amyotrophic lateral sclerosis. Neurodegeneration 1995; 4: 397–401.
   PubMedGoogle Scholar
• Nagaraja TN, Gourie-Devi M, Nalini A, Raju TR. Neurofilament phosphorylation is enhanced in cultured chick spinal cord neurons exposed to cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neuropathol (Berl) 1994; 88: 349–352.
   PubMed Web of Science ®Google Scholar
• Couratier P, Hugon J, Sindou P, Vallat JM, Dumas M. Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet 1993; 341: 265–268.
   PubMed Web of Science ®Google Scholar
• Manabe Y, Kashihara K, Shiro Y, Shohmori T, Abe K. Enhanced Fos expression in rat lumbar spinal cord cultured with cerebrospinal fluid from patients with amyotrophic lateral sclerosis. Neurol Res 1999; 21: 309–312.
   PubMed Web of Science ®Google Scholar
• Shaw PJ. Toxicity of CSF in motor neurone disease: a potential route to neuroprotection. Brain 2002; 125: 693–694.
   PubMedGoogle Scholar
• Tikka TM, Vartiainen NE, Goldsteins G et al. Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 2002; 125: 722–731.
   Google Scholar
• Terro F, Lesort M, Viader F, Ludolph A, Hugon J. Antioxidant drugs block in vitro the neurotoxicity of CSF from patients with amyotrophic lateral sclerosis. Neuroreport 1996; 7: 1970–1972.
   PubMed Web of Science ®Google Scholar
• Magyar K, Szende B, Lengyel J, Tarczali J, Szatmary I. The neuroprotective and neuronal rescue effects of (-)-deprenyl. J Neural Transm (suppl) 1998; 52: 109–123.
   PubMedGoogle Scholar
• Gerlach M, Riederer P, Youdim MB. The molecular pharmacol- ogy of L-deprenyl. Eur J Pharmacol 1992; 226: 97–108.
   PubMedGoogle Scholar
• Koller WC. Neuroprotective therapy for Parkinson’s disease. Exp Neurol 1997; 144: 24–28.
   PubMedGoogle Scholar
• Rinne JO, Roytta M, Paljarvi L, Rummukainen J, Rinne UK. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson’s disease. Neurology 1991; 41: 859–861.
   PubMedGoogle Scholar
• Thomas T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer’s disease. Neurobiol Aging 2000; 21: 343–348.
   PubMed Web of Science ®Google Scholar
• Birks J, Flicker L. Selegiline for Alzheimer’s disease. Cochrane Database Syst Rev 2003: CD000442.
   Google Scholar
• Filip V, Kolibas E. Selegiline in the treatment of Alzheimer’s disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group. J Psychiatry Neurosci 1999; 24: 234–243.
   Google Scholar
• Freedman M, Rewilak D, Xerri T et al. L-deprenyl in Alzheimer’s disease: cognitive and behavioural effects. Neurology 1998; 50: 660–668.
   Google Scholar
• Vizuete ML, Steffen V, Ayala A, Cano J, Machado A. Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neuro- toxicity in rat striatum. Neurosci Lett 1993; 152: 113–116.
   PubMedGoogle Scholar
• Suuronen T, Kolehmainen P, Salminen A. Protective effect of L-deprenyl against apoptosis induced by okadic acid in cultured neuronal cells. Biochem Pharmacol 2000; 59: 1589–1595.
   PubMedGoogle Scholar
• Yu AC, Lee YL, Eng LF. Inhibition of GFAP synthesis by antisense RNA in astrocytes. J Neurosci Res 1991; 30: 72–79.
   PubMedGoogle Scholar
• Matsui Y, Kumagae Y. Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischaemia. Neurosci Lett 1991; 126: 175–178.
   PubMed Web of Science ®Google Scholar
• Munirathinam S, Lakshmana MK, Raju TR. (-)-Deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures. Neurodegeneration 1996; 5: 161–167.
   PubMedGoogle Scholar
• Ju WY, Holland DP, Tatton WG. (-)-Deprenyl alters the time course of death of axotomised facial motoneurons and the hypertrophy of neighbouring astrocytes in immature rats. Exp Neurol 1994; 126: 233–246.
   PubMedGoogle Scholar
• Oh C, Murray B, Bhattacharya N, Holland D, Tatton WG. (-)-Deprenyl alters the survival of adult murine facial motoneur- ons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. J Neurosci Res 1994; 38: 64–74.
   PubMed Web of Science ®Google Scholar
• Ansari KS, Yu PH, Kruck TP, Tatton WG. Rescue of axotomised immature rat facial motoneurons by R(-)-deprenyl: stereospeci- ficity and independence from monoamine oxidase inhibition. J Neurosci 1993; 13: 4042–4053.
   PubMed Web of Science ®Google Scholar
• Salo PT, Tatton WG. Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res 1992; 31: 394–400.
   PubMed Web of Science ®Google Scholar
• Ravikumar R, Lakshmana MK, Rao BS, Meti BL, Bindu PN, Raju TR. (-)-Deprenyl attenuates spinal motor neuron degeneration and associated locomotor deficits in rats subjected to spinal cord ischaemia. Exp Neurol 1998; 149: 123–129.
   PubMedGoogle Scholar
• Kiran B, Rao BS, Raju TR, Bindu PN. Spinal cord ischaemia induced neurotoxicity and neurodegeaneration: attenuation by (-)-deprenyl and magnesium sulphate. Medical Science Research 1998; 26: 89–92.
   Google Scholar
• Iwasaki Y, Ikeda K, Shiojima T, Kobayashi T, Tagaya N, Kinoshita M. Deprenyl enhances neurite outgrowth in cultured rat spinal ventral horn neurons. J Neurol Sci 1994; 125: 11–13.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293–299.
   PubMed Web of Science ®Google Scholar
• Munetto V, Sternberger NH, Perry G, Sternberger LA, Gambetti P. Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1988; 47: 642–653.
   PubMedGoogle Scholar
• Gold BG, Austin DR, Griffin JW. Regulation of aberrant neurofilament phosphorylation in neuronal perikarya. I and II. J Neuropathol Exp Neurol 1991; 50: 626–645.
   Google Scholar
• Iwasaki Y, Ikeda K, Shiojima T, Kobayashi T, Tagaya N, Kinoshita M.Deprenyl and pergolide rescue spinal motor neurons from axotomy-induced neuronal death in the neonatal rat. Neurol Res 1996; 18: 168–170.
   PubMedGoogle Scholar
• Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002; 24: 675–682.
   PubMed Web of Science ®Google Scholar
• Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, Tatton NA. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm (suppl) 1996; 48: 45–59.
   PubMedGoogle Scholar
• Li XM, Juorio AV, Boulton AA. Some new mechanisms under- lying the actions of (-)-deprenyl: possible relevance to neurode- generation. Prog Brain Res 1995; 106: 99–112.
   PubMed Web of Science ®Google Scholar
• Tatton WG, Ju WY, Holland DP, Tai C, Kwan M. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 1994; 63: 1572–1575.
   PubMed Web of Science ®Google Scholar
• Julien JP. Neurofilament functions in health and disease. Curr Opin Neurobiol 1999; 9: 554–560.
   PubMed Web of Science ®Google Scholar
• Straube-West K, Loomis PA, Opal P, Goldman RD. Alterations in neural intermediate filament organization: functional implica- tions and the induction of pathological changes related to motor neurone disease. J Cell Sci 1996; 109: 2319–2329.
   PubMedGoogle Scholar
• Julien JP. A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem Cell Biol 1995; 73: 593–597.
   PubMed Web of Science ®Google Scholar
• Mizusawa H, Matsumoto S, Yen SH, Hirano A, Rojas-Corona RR, Donnenfeld H. Focal accumulation of phosphorylated neurofila- ments within anterior horn cell in familial amyotrophic lateral sclerosis. Acta Neuropathol (Berl) 1989; 79: 37–43.
   PubMed Web of Science ®Google Scholar
• Munoz DG, Greene C, Perl DP, Selkoe DJ. Accumulation of phosphorylated neurofilaments in anterior horn motoneurons of amyotrophic lateral sclerosis patients. J Neuropathol Exp Neurol 1988; 47: 9–18.
   PubMed Web of Science ®Google Scholar
• Pant HC, Veeranna. Neurofilament phosphorylation. Biochem Cell Biol 1995; 73: 575–592.
   PubMed Web of Science ®Google Scholar
• Kesavapany S, Li BS, Pant HC. Cyclin-dependent kinase 5 in neurofilament function and regulation. Neurosignals 2003; 12: 252–264.
   PubMedGoogle Scholar
• Veeranna, Amin ND, Ahn NG et al. Mitogen-activated protein kinases (Erk1, 2) phosphorylate Lys-Ser-Pro (KSP) repeats in neurofilament proteins NF-H and NF-M. J Neurosci 1998; 18: 4008–4021.
   Google Scholar
• Veeranna, Shetty KT, Link WT, Jaffe H, Wang J, Pant HC. Neuronal cyclin-dependent kinase-5 phosphorylation sites in neurofilament protein (NF-H) are dephosphorylated by protein phosphatase 2A. J Neurochem 1995; 64: 2681–2690.
   PubMedGoogle Scholar
• Mizuta I, Ohta M, Nishimura M, Mizuta E, Hayashi K, Kuno S. Selegine and desmethylselegine stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun 2000; 279: 751–755.
   PubMed Web of Science ®Google Scholar
• Tatton WG, Chalmers-Redman RM, Ju WY, Wadia J, Tatton NA. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm (suppl) 1997; 49: 245–268.
   PubMedGoogle Scholar
• Pereira CF, Oliveira CR. Oxidative glutamate toxicity involves mitochondrial dysfunction and perturbation of intracellular Ca2z homeostasis. Neurosci Res 2000; 37: 227–236.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH, Parks JK, Pattee G, Parker WD, Jr. Role of mitochondria in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 185–190.
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Shiojima T, Ikeda K, Kinoshita M. Bromocriptine prevents spinal motor neuron death following sciatic nerve transection in neonatal rats. Neurosci Lett 1996; 214: 139–142.
   PubMedGoogle Scholar
• Wu RM, Chen RC, Chiueh CC. Effect of MAO-B inhibitors on MPPz toxicity in vivo. Ann N Y Acad Sci 2000; 899: 255–261.
   PubMed Web of Science ®Google Scholar
• Wadia JS, Chalmers-Redman RM, Ju WJ et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J Neurosci 1998; 18: 932–947.
   Google Scholar
• Wu RM, Murphy DL, Chiueh CC. Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline). Ann N Y Acad Sci 1996; 786: 379–390.
   PubMedGoogle Scholar
• Eddleston M, Mucke L. Molecular profile of reactive astrocytes: implications for their role in neurological disease. Neuroscience 1993; 54: 15–36.
   PubMed Web of Science ®Google Scholar
• Li XM, Qi J, Juorio AV, Boulton AA. Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-deprenyl and other monoamine oxidase B inhibitors in C6 glioma cells. J Neurochem 1993; 61: 1573–1576.
   PubMedGoogle Scholar
• Amenta F, Bograni S, Cadel S, Ferrante F, Valsecchi B, Vega JA. Microanatomical changes in the frontal cortex of aged rats: effect of L-deprenyl treatment. Brain Res Bull 1994; 34: 125–131.
   PubMedGoogle Scholar
• Shimazu S, Tanigawa A, Sato N, Yoneda F, Hayashi K, Knoll J. Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2- propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. Life Sci 2003; 72: 2785–2792.
   PubMedGoogle Scholar
• Xu L, Ma J, Seigel GM, Ma JX. l-Deprenyl, blocking apoptosis and regulating gene expression in cultured retinal neurons. Biochem Pharmacol 1999; 58: 1183–1190.
   PubMedGoogle Scholar
• Riva MA, Molteni R, Racagni G. L-deprenyl potentiates cAMP- induced elevation of FGF-2 mRNA levels in rat cortical astro- cytes. Neuroreport 1997; 8: 2165–2168.
   PubMedGoogle Scholar
• Tatton WG, Chalmers-Redman RM. Modulation of gene expres- sion rather than monoamine oxidase inhibition: (-)-deprenyl- related compounds in controlling neurodegeneration. Neurology 1996; 47: S171–183.
   Web of Science ®Google Scholar
• Lange DJ, Murphy PL, Diamond B et al. Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 1998; 55: 93–96.
   Google Scholar
• Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE, Aquilonius SM. Double-blind cross-over trial with deprenyl in amyotrophic lateral sclerosis. J Neural Transm (suppl) 1994; 41: 237–241.
   PubMedGoogle Scholar
• Mazzini L, Testa D, Balzarini C, Mora G. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis. J Neurol 1994; 241: 223–227.
   PubMed Web of Science ®Google Scholar